(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.
The three biggest winners today are FibroGen, Banco Bradesco, and Inovio Pharmaceuticals.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | FibroGen (FGEN) | 1.91 | 7.91% | 2023-08-08 04:09:14 |
| 2 | Banco Bradesco (BBDO) | 2.94 | 5% | 2023-08-08 04:38:02 |
| 3 | Inovio Pharmaceuticals (INO) | 0.44 | 3.53% | 2023-08-08 04:10:18 |
| 4 | Aurora Cannabis (ACB) | 0.55 | 1.29% | 2023-08-08 04:46:22 |
| 5 | NeuroMetrix (NURO) | 0.88 | 1.15% | 2023-08-08 04:35:56 |
| 6 | Ambev (ABEV) | 2.99 | 1.01% | 2023-08-08 04:37:15 |
| 7 | AB InBev (BUD) | 56.90 | 0.82% | 2023-08-08 04:38:36 |
| 8 | Exelon (EXC) | 40.17 | 0.5% | 2023-08-08 04:36:45 |
| 9 | iShares (PFF) | 30.77 | 0.07% | 2023-08-08 04:14:11 |
| 10 | Vanguard Total International Bond (BNDX) | 48.40 | 0% | 2023-08-08 04:08:05 |
The three biggest losers today are Sypris Solutions, Banco Bilbao Vizcaya Argentaria, and Celanese.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | Sypris Solutions (SYPR) | 1.92 | -4% | 2023-08-08 04:36:09 |
| 2 | Banco Bilbao Vizcaya Argentaria (BBVA) | 7.52 | -2.34% | 2023-08-08 04:15:48 |
| 3 | Celanese (CE) | 122.00 | -2.19% | 2023-08-08 04:38:55 |
| 4 | ING Group (ING) | 14.58 | -1.69% | 2023-08-08 04:41:09 |
| 5 | Home Depot (HD) | 323.90 | -1.6% | 2023-08-08 04:40:45 |
| 6 | SK Telecom (SKM) | 19.80 | -1.35% | 2023-08-08 04:19:24 |
| 7 | UBS Group (UBS) | 21.95 | -0.99% | 2023-08-08 04:45:04 |
| 8 | Novo Nordisk A/S (NVO) | 160.35 | -0.63% | 2023-08-08 04:18:50 |
| 9 | Teva Pharmaceutical (TEVA) | 9.58 | -0.52% | 2023-08-08 04:44:37 |
| 10 | First Majestic Silver (AG) | 5.93 | -0.5% | 2023-08-08 04:37:22 |
Premarket Winners today
1. FibroGen (FGEN) – Premarket: 7.91%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen sliding 7.59% to $1.77 on Tuesday, following the last session’s downward trend. NASDAQ rose 0.61% to $13,994.40, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.84.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -411.93%.
Moving Average
FibroGen’s worth is way below its 50-day moving average of $10.16 and way below its 200-day moving average of $16.33.
Volatility
FibroGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.16%, a negative 2.07%, and a positive 3.02%.
FibroGen’s highest amplitude of average volatility was 3.96% (last week), 3.87% (last month), and 3.02% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is -19.6.
Yearly Top and Bottom Value
FibroGen’s stock is valued at $1.77 at 08:34 EST, below its 52-week low of $1.82.
Previous days news about FibroGen
- Fibrogen (fgen) reports Q2 loss, tops revenue estimates. According to Zacks on Monday, 7 August, "While FibroGen has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about FibroGen.
2. Banco Bradesco (BBDO) – Premarket: 5%
Banco Bradesco S.A., together with its subsidiaries, provides various banking products and services to individuals, corporates, and businesses in Brazil and internationally. The company operates through two segments, Banking and Insurance. It provides current, savings, click, and salary accounts; real estate credit, vehicle financing, payroll loans, mortgage loans, microcredit, leasing, and personal and installment credit; debit and business cards; financial and security services; consortium products; auto, personal accident, dental, travel, and life insurance; investment products; pension products; real estate and vehicle auctions; cash management, and foreign trade and exchange services; capitalization bonds; and internet banking services. Banco Bradesco S.A. was founded in 1943 and is headquartered in Osasco, Brazil.
NYSE ended the session with Banco Bradesco falling 1.41% to $2.80 on Tuesday while NYSE jumped 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Banco Bradesco has a trailing twelve months EPS of $0.34.
PE Ratio
Banco Bradesco has a trailing twelve months price to earnings ratio of 8.24. Meaning, the purchaser of the share is investing $8.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.73%.
Moving Average
Banco Bradesco’s value is below its 50-day moving average of $2.91 and above its 200-day moving average of $2.62.
Volatility
Banco Bradesco’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.53%, a negative 0.07%, and a positive 1.96%.
Banco Bradesco’s highest amplitude of average volatility was 2.53% (last week), 1.82% (last month), and 1.96% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 25.3%, now sitting on 79.54B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Aug 1, 2023, the estimated forward annual dividend rate is 0.17 and the estimated forward annual dividend yield is 5.7%.
More news about Banco Bradesco.
3. Inovio Pharmaceuticals (INO) – Premarket: 3.53%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals dropping 5.3% to $0.43 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ jumped 0.61% to $13,994.40, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.01.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.1%.
Yearly Top and Bottom Value
Inovio Pharmaceuticals’s stock is valued at $0.43 at 08:34 EST, way below its 52-week high of $2.82 and way higher than its 52-week low of $0.38.
Volume
Today’s last reported volume for Inovio Pharmaceuticals is 1630440 which is 82.03% below its average volume of 9074270.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 69.6% and 13.3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth declined by 42.3%, now sitting on 10.18M for the twelve trailing months.
More news about Inovio Pharmaceuticals.
4. Aurora Cannabis (ACB) – Premarket: 1.29%
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.
NYSE ended the session with Aurora Cannabis falling 1.79% to $0.54 on Tuesday while NYSE jumped 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-5.92.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Aurora Cannabis’s stock is considered to be overbought (>=80).
Volatility
Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.85%, a negative 0.09%, and a positive 3.40%.
Aurora Cannabis’s highest amplitude of average volatility was 2.93% (last week), 2.70% (last month), and 3.40% (last quarter).
More news about Aurora Cannabis.
5. NeuroMetrix (NURO) – Premarket: 1.15%
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
NASDAQ ended the session with NeuroMetrix dropping 1.15% to $0.87 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.61% to $13,994.40, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.69.
Moving Average
NeuroMetrix’s worth is way under its 50-day moving average of $0.99 and way below its 200-day moving average of $1.45.
Volume
Today’s last reported volume for NeuroMetrix is 7472 which is 93.18% below its average volume of 109716.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NeuroMetrix’s stock is considered to be overbought (>=80).
More news about NeuroMetrix.
6. Ambev (ABEV) – Premarket: 1.01%
Ambev S.A., through its subsidiaries, engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, other non-alcoholic beverages, malt, and food products. It offers beer primarily under the Skol, Brahma, Antarctica, Brahva, Budweiser, Bud Light, Beck, Leffe and Hoegaarden, Bucanero, Cristal, Mayabe, Presidente, Presidente Light, Brahma Light, Bohemia, The One, Corona, Modelo Especial, Stella Artois, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Cusqueña, Michelob Ultra, Busch, Pilsen, Ouro Fino, Banks, Deputy, Patricia, Labatt Blue, Alexander Keith's, and Kokanee brands. The company also provides carbonated soft drinks, bottled water, isotonic beverages, energy drinks, coconut water, powdered and natural juices, and ready-to-drink teas under the Guaraná Antarctica, Gatorade, H2OH!, Lipton Iced Tea, Fusion, Do Bem, Pepsi-Cola, Canada Dry, Squirt, Red Rock, Red Bull, Seven Up, Nutrl, Bud Light Seltzer, Palm Bay, and Mike's brands. It offers its products through a network of third-party distributors and a direct distribution system. The company was founded in 1885 and is headquartered in São Paulo, Brazil. Ambev S.A. operates as a subsidiary of Interbrew International B.V.
NYSE ended the session with Ambev falling 0.84% to $2.96 on Tuesday while NYSE rose 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Ambev has a trailing twelve months EPS of $0.19.
PE Ratio
Ambev has a trailing twelve months price to earnings ratio of 15.55. Meaning, the purchaser of the share is investing $15.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.22%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Ambev’s stock is considered to be overbought (>=80).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ambev’s EBITDA is 6.92.
Volume
Today’s last reported volume for Ambev is 6281190 which is 56.31% below its average volume of 14377500.
Volatility
Ambev’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.18%, a negative 0.09%, and a positive 1.28%.
Ambev’s highest amplitude of average volatility was 1.69% (last week), 1.24% (last month), and 1.28% (last quarter).
More news about Ambev.
7. AB InBev (BUD) – Premarket: 0.82%
Anheuser-Busch InBev SA/NV produces, distributes, markets, and sells beer and beverages. It offers a portfolio of approximately 500 beer brands, which primarily include Budweiser, Corona, and Stella Artois; Beck's, Hoegaarden, Leffe, and Michelob Ultra; and Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol brands. The company was founded in 1366 and is headquartered in Leuven, Belgium.
NYSE ended the session with AB InBev dropping 0.08% to $56.44 on Tuesday while NYSE rose 0.85% to $16,208.23.
Earnings Per Share
As for profitability, AB InBev has a trailing twelve months EPS of $3.67.
PE Ratio
AB InBev has a trailing twelve months price to earnings ratio of 15.38. Meaning, the purchaser of the share is investing $15.38 for every dollar of annual earnings.
Sales Growth
AB InBev’s sales growth is 4.3% for the current quarter and 6.4% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 6.8% and positive 7.1% for the next.
Yearly Top and Bottom Value
AB InBev’s stock is valued at $56.44 at 08:34 EST, way below its 52-week high of $67.09 and way above its 52-week low of $44.51.
Volatility
AB InBev’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.18%, a positive 0.08%, and a positive 1.11%.
AB InBev’s highest amplitude of average volatility was 0.84% (last week), 0.84% (last month), and 1.11% (last quarter).
More news about AB InBev.
8. Exelon (EXC) – Premarket: 0.5%
Exelon Corporation, a utility services holding company, engages in the energy distribution and transmission businesses in the United States and Canada. The company is involved in the purchase and regulated retail sale of electricity and natural gas, transmission and distribution of electricity, and distribution of natural gas to retail customers. It also offers support services, including legal, human resources, information technology, supply management, financial, engineering, customer operations, distribution and transmission planning, asset management, system operations, and power procurement services. It serves distribution utilities, municipalities, cooperatives, and financial institutions, as well as commercial, industrial, governmental, and residential customers. Exelon Corporation was incorporated in 1999 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with Exelon jumping 0.14% to $39.97 on Tuesday while NASDAQ jumped 0.61% to $13,994.40.
Earnings Per Share
As for profitability, Exelon has a trailing twelve months EPS of $2.26.
PE Ratio
Exelon has a trailing twelve months price to earnings ratio of 17.69. Meaning, the purchaser of the share is investing $17.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.23%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 13, 2023, the estimated forward annual dividend rate is 1.44 and the estimated forward annual dividend yield is 3.43%.
Volume
Today’s last reported volume for Exelon is 2179370 which is 65.24% below its average volume of 6270110.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Exelon’s stock is considered to be overbought (>=80).
Sales Growth
Exelon’s sales growth is negative 2.6% for the ongoing quarter and 2.6% for the next.
More news about Exelon.
9. iShares (PFF) – Premarket: 0.07%
NASDAQ ended the session with iShares rising 0.21% to $30.75 on Tuesday, after two successive sessions in a row of gains. NASDAQ jumped 0.61% to $13,994.40, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, iShares has a trailing twelve months EPS of $6.78.
PE Ratio
iShares has a trailing twelve months price to earnings ratio of 3.81. Meaning, the purchaser of the share is investing $3.81 for every dollar of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, iShares’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for iShares is 1864680 which is 40.84% below its average volume of 3152130.
Volatility
iShares’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.11%, a positive 0.02%, and a positive 0.47%.
iShares’s highest amplitude of average volatility was 0.54% (last week), 0.49% (last month), and 0.47% (last quarter).
More news about iShares.
10. Vanguard Total International Bond (BNDX) – Premarket: 0%
NASDAQ ended the session with Vanguard Total International Bond dropping 0.21% to $48.40 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.61% to $13,994.40, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Vanguard Total International Bond has a trailing twelve months EPS of $1.83.
Volume
Today’s last reported volume for Vanguard Total International Bond is 949352 which is 58.14% below its average volume of 2268190.
More news about Vanguard Total International Bond.
Premarket Losers Today
1. Sypris Solutions (SYPR) – Premarket: -4%
Sypris Solutions, Inc. engages in the provision of truck components, oil and gas pipeline components, and aerospace and defense electronics primarily in North America and Mexico. It operates in two segments, Sypris Technologies and Sypris Electronics. The Sypris Technologies segment supplies forged, machined, welded, and heat-treated steel components for the commercial vehicle, off highway vehicle, recreational vehicle, automotive, industrial, light truck, and energy markets. This segment also offers drive train components, including axle shafts, transmission shafts, gear sets, steer axle knuckles, and other components for automotive, truck, and recreational vehicle manufacturers. In addition, the segment provides value added operations for drive train assemblies; and manufactures pressurized closures, insulated joints, and other fabricated and specialty products for oil and gas pipelines and related energy markets. The Sypris Electronics segment offers electronic manufacturing services, such as circuit card and full box build manufacturing, high reliability manufacturing, systems assembly and integration, design for manufacturability, and design for specification work for aerospace and defense electronics markets. This segment also provides circuit card assembly services for electronic sensors and systems, including radar systems, tactical ground stations, navigation systems, weapons systems, and targeting and warning systems; and value-added solutions, such as low-volume prototype assembly and high-volume turnkey manufacturing. The company also offers engineering design and repair or inspection services. In addition, it sells its engineered product under the Tube Turns brand. The company was incorporated in 1997 and is headquartered in Louisville, Kentucky.
NASDAQ ended the session with Sypris Solutions jumping 4.59% to $2.00 on Tuesday while NASDAQ rose 0.61% to $13,994.40.
Earnings Per Share
As for profitability, Sypris Solutions has a trailing twelve months EPS of $-0.13.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.09%.
Yearly Top and Bottom Value
Sypris Solutions’s stock is valued at $2.00 at 08:34 EST, way under its 52-week high of $2.30 and way above its 52-week low of $1.71.
More news about Sypris Solutions.
2. Banco Bilbao Vizcaya Argentaria (BBVA) – Premarket: -2.34%
Banco Bilbao Vizcaya Argentaria, S.A., together with its subsidiaries, provides retail banking, wholesale banking, and asset management services. It offers current accounts; and demand, savings, overnight, time, term, and subordinated deposits. The company also provides loan products; deals in securities; leasing, factoring, brokerage, and asset management services; and manages pension and investment funds. In addition, it offers credit cards; corporate and investment banking services; insurance products and services; and real estate services. The company provides its products through online and mobile channels. It operates in Spain, Mexico, South America, the United States, Turkey, Asia, and rest of Europe. Banco Bilbao Vizcaya Argentaria, S.A. was founded in 1857 and is headquartered in Bilbao, Spain.
NYSE ended the session with Banco Bilbao Vizcaya Argentaria rising 1.18% to $7.70 on Tuesday while NYSE rose 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Banco Bilbao Vizcaya Argentaria has a trailing twelve months EPS of $1.22.
PE Ratio
Banco Bilbao Vizcaya Argentaria has a trailing twelve months price to earnings ratio of 6.31. Meaning, the purchaser of the share is investing $6.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.04%.
Moving Average
Banco Bilbao Vizcaya Argentaria’s value is above its 50-day moving average of $7.40 and way above its 200-day moving average of $6.72.
Volume
Today’s last reported volume for Banco Bilbao Vizcaya Argentaria is 511499 which is 57.38% below its average volume of 1200400.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Banco Bilbao Vizcaya Argentaria’s stock is considered to be oversold (<=20).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 2, 2023, the estimated forward annual dividend rate is 0.46 and the estimated forward annual dividend yield is 5.67%.
More news about Banco Bilbao Vizcaya Argentaria.
3. Celanese (CE) – Premarket: -2.19%
Celanese Corporation, a chemical and specialty materials company, manufactures and sells high performance engineered polymers in the United States and internationally. The company operates through Engineered Materials and Acetyl Chain. The Engineered Materials segment develops, produces, and supplies specialty polymers for automotive and medical applications, as well as for use in industrial products and consumer electronics. It also offers acesulfame potassium for the food and beverage industry, and food protection ingredients, such as potassium sorbate and sorbic acid. The Acetyl Chain segment produces and supplies acetyl products, including acetic acid, vinyl acetate monomers, acetic anhydride, and acetate esters that are used as starting materials for colorants, paints, adhesives, coatings, and pharmaceuticals; and organic solvents and intermediates for pharmaceutical, agricultural, and chemical products. It also offers vinyl acetate-based emulsions for use in paints and coatings, adhesives, construction, glass fiber, textiles, and paper applications; and ethylene vinyl acetate resins and compounds, as well as low-density polyethylene for use in flexible packaging films, lamination film products, hot melt adhesives, automotive parts, and carpeting applications. In addition, it manufactures ultra-high molecular weight polyethylene. Celanese Corporation was founded in 1918 and is headquartered in Irving, Texas.
NYSE ended the session with Celanese rising 0.63% to $124.73 on Tuesday while NYSE jumped 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Celanese has a trailing twelve months EPS of $13.66.
PE Ratio
Celanese has a trailing twelve months price to earnings ratio of 9.13. Meaning, the purchaser of the share is investing $9.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.11%.
Previous days news about Celanese
- Celanese (ce) Q2 earnings and revenues miss estimates. According to Zacks on Monday, 7 August, "While Celanese has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Celanese (ce) reports Q2 earnings: what key metrics have to say. According to Zacks on Monday, 7 August, "Here is how Celanese performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Celanese.
4. ING Group (ING) – Premarket: -1.69%
ING Groep N.V., a financial institution, provides various banking products and services in the Netherlands, Belgium, Rest of Europe, North America, Latin America, Asia, and Australia. It operates in six segments: Retail Netherlands, Retail Belgium, Retail Germany, Retail Other, Wholesale Banking, and Corporate Line Banking. The company accepts various deposits, such as current and savings accounts. It also offers business lending products; consumer lending products, such as residential mortgage loans, term loans, and other consumer lending loans; and secured and unsecured lending services. in addition, the company provides debt capital market, working capital solutions, export finance, daily banking, treasury and risk, and corporate finance solutions; and specialized lending, debt and equity market solutions, payments and cash management, and trade and treasury services, as well as savings, investment, insurance, mortgage, and digital banking services; and SME loans. It serves individual customers, corporate clients, and financial institutions. ING Groep N.V. was founded in 1762 and is headquartered in Amsterdam, the Netherlands.
NYSE ended the session with ING Group jumping 1.06% to $14.83 on Tuesday while NYSE rose 0.85% to $16,208.23.
Earnings Per Share
As for profitability, ING Group has a trailing twelve months EPS of $1.5.
PE Ratio
ING Group has a trailing twelve months price to earnings ratio of 9.88. Meaning, the purchaser of the share is investing $9.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.17%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 4.09%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ING Group’s stock is considered to be oversold (<=20).
More news about ING Group.
5. Home Depot (HD) – Premarket: -1.6%
The Home Depot, Inc. operates as a home improvement retailer. It sells various building materials, home improvement products, lawn and garden products, and décor products, as well as facilities maintenance, repair, and operations products. The company also offers installation services for flooring, water heaters, bath, garage doors, cabinets, cabinet makeovers, countertops, sheds, furnaces and central air systems, and windows. In addition, it provides tool and equipment rental services. The company primarily serves homeowners; and professional renovators/remodelers, general contractors, maintenance professionals, handymen, property managers, and building service contractors, as well as specialty tradesmen, such as electricians, plumbers, and painters. It also sells its products through websites, including homedepot.com; homedepot.ca and homedepot.com.mx; blinds.com, an online site for custom window coverings; and thecompanystore.com, an online site for textiles and décor products, as well as through The Home Depot stores. The Home Depot, Inc. was incorporated in 1978 and is based in Atlanta, Georgia.
NYSE ended the session with Home Depot jumping 0.84% to $329.17 on Tuesday while NYSE jumped 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Home Depot has a trailing twelve months EPS of $16.43.
PE Ratio
Home Depot has a trailing twelve months price to earnings ratio of 20.03. Meaning, the purchaser of the share is investing $20.03 for every dollar of annual earnings.
Sales Growth
Home Depot’s sales growth for the current quarter is negative 3.6%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 4.2%, now sitting on 155.75B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Home Depot’s EBITDA is 55.19.
Moving Average
Home Depot’s value is higher than its 50-day moving average of $305.38 and higher than its 200-day moving average of $304.13.
More news about Home Depot.
6. SK Telecom (SKM) – Premarket: -1.35%
SK Telecom Co., Ltd. provides wireless telecommunication services in South Korea. The company operates through three segments: Cellular Services, Fixed-Line Telecommunications Services, and Other Businesses. The Cellular Services segment offers wireless voice and data transmission, Internet of Things solutions, platform, cloud, smart factory solutions, subscription, advertising and curated shopping under T Deal brand name, and metaverse platform-based services, as well as sells wireless devices. The Fixed-Line Telecommunications Services segment provides fixed-line telephone services; broadband Internet services; media platform services, such as Internet protocol TV and cable TV; and business communications services. The Other Businesses segment offers T-commerce services, as well as portal services under Nate brand name. In addition, it provides call center management, base station maintenance, information gathering and consulting, database and internet website, cable broadcasting, broadcasting programs, and digital contents sourcing services; manufactures non-memory and other electronic integrated circuits; and operates information and communications facilities, and mobile virtual network, as well as engages in communications and other telecommunication device retail business. The company was incorporated in 1984 and is headquartered in Seoul, South Korea.
NYSE ended the session with SK Telecom jumping 1.65% to $20.07 on Tuesday, after four sequential sessions in a row of gains. NYSE jumped 0.85% to $16,208.23, following the last session’s upward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, SK Telecom has a trailing twelve months EPS of $1.93.
PE Ratio
SK Telecom has a trailing twelve months price to earnings ratio of 10.4. Meaning, the purchaser of the share is investing $10.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.38%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.2%, now sitting on 17.4T for the twelve trailing months.
More news about SK Telecom.
7. UBS Group (UBS) – Premarket: -0.99%
UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through four divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, and Investment Bank. The Global Wealth Management division offers investment advice and solutions, and lending solutions. This segment also provides estate and wealth planning, investing, corporate and banking, and investment management, as well as mortgage, securities-based, and structured lending solutions. The Personal & Corporate Banking division provides personal banking products and services, such as deposits, cards, and online and mobile banking, as well as lending, investments, and retirement services; and corporate and institutional solutions, including equity and debt capital markets, syndicated and structured credit, private placements, leasing, traditional financing, trade and export finance, and global custody solutions, as well as transaction banking solutions for payment and cash management. The Asset Management division offers equities, fixed income, hedge funds, real estate and private markets, indexed and alternative beta strategies, asset allocation and currency investment strategies, customized multi-asset solutions, advisory and fiduciary services, and multi-manager hedge fund solutions and advisory services. The Investment Bank division advises clients on strategic business opportunities and helps them raise capital to fund their activities; enables its clients to buy, sell, and finance securities on capital markets and to manage their risks and liquidity; distribute, trade, finance, and clear cash equities and equity-linked products; and offers clients differentiated content on major financial markets and securities. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is based in Zurich, Switzerland.
NYSE ended the session with UBS Group jumping 1.3% to $22.17 on Tuesday, after five sequential sessions in a row of gains. NYSE jumped 0.85% to $16,208.23, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, UBS Group has a trailing twelve months EPS of $1.96.
PE Ratio
UBS Group has a trailing twelve months price to earnings ratio of 11.31. Meaning, the purchaser of the share is investing $11.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.27%.
Yearly Top and Bottom Value
UBS Group’s stock is valued at $22.17 at 08:34 EST, under its 52-week high of $22.30 and way above its 52-week low of $13.80.
More news about UBS Group.
8. Novo Nordisk A/S (NVO) – Premarket: -0.63%
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NYSE ended the session with Novo Nordisk A/S jumping 3.04% to $161.36 on Tuesday, after two sequential sessions in a row of gains. NYSE jumped 0.85% to $16,208.23, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $4.06.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 39.74. Meaning, the purchaser of the share is investing $39.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 83.5%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 61.5% and 44%, respectively.
Volume
Today’s last reported volume for Novo Nordisk A/S is 883468 which is 30.01% below its average volume of 1262280.
Yearly Top and Bottom Value
Novo Nordisk A/S’s stock is valued at $161.36 at 08:34 EST, below its 52-week high of $172.97 and way above its 52-week low of $95.02.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 23, 2023, the estimated forward annual dividend rate is 1.76 and the estimated forward annual dividend yield is 1.07%.
More news about Novo Nordisk A/S.
9. Teva Pharmaceutical (TEVA) – Premarket: -0.52%
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
NYSE ended the session with Teva Pharmaceutical falling 1.33% to $9.63 on Tuesday while NYSE rose 0.85% to $16,208.23.
Earnings Per Share
As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-1.42.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.93%.
More news about Teva Pharmaceutical.
10. First Majestic Silver (AG) – Premarket: -0.5%
First Majestic Silver Corp. engages in the acquisition, exploration, development, and production of mineral properties with a focus on silver and gold production in North America. Its projects include the San Dimas mine that consists of 119 individual concessions covering an area of 71,839 hectares located in Durango and Sinaloa States, México; the Santa Elena comprising 32 individual concessions that covers an area of 102,172 hectares located in Sonora State, México; and the La Encantada consists of 22 exploitation concessions covering an area of 4,076 hectares located in Coahuila State, México. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was incorporated in 1979 and is headquartered in Vancouver, Canada.
NYSE ended the session with First Majestic Silver dropping 1.81% to $5.96 on Tuesday, following the last session’s downward trend. NYSE jumped 0.85% to $16,208.23, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, First Majestic Silver has a trailing twelve months EPS of $-0.81.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.05%.
Yearly Top and Bottom Value
First Majestic Silver’s stock is valued at $5.96 at 08:34 EST, way below its 52-week high of $9.81 and way above its 52-week low of $5.24.
More news about First Majestic Silver.
Stay up to date with our premarket winners and losers daily report
